TYRA
Tyra Biosciences, Inc.
$30.62
+1.21 (+4.11%)
At close · Jul 2
Market Cap
$1.82B
Shares
59,470,381
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$30.62
Open$29.71
Day$29.33–30.78
52W$9.47–40.65
Avg vol 30d1.0M
Short int9.9M · 16.6% float · 9.2d
Short vol56%
Last earningsMay 13, 2026
DataSep 2021–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+13% above
◦
Price vs 50-day avg
−4% below
◦
RSI (14)
51 · neutral
+
MACD trend
positive
◦
52-week position
68% · mid-range
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $32 › 200d $27 — 50d above 200d
◦
Institutional flow
1 of 163 funds reported for Jun 30 · net 0 sh shares
◦
Insider flow
No net insider activity over 90 days
−
Short interest
16.59% of float · ▲ +6.3% MoM · 9.2 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
163 holders — near 3-yr high, broad support
Fundamentals
Weak
−
EPS growth
−33% Y/Y
−
Free cash flow
$-95.3M
+
Balance sheet
net cash $77.4M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+13% above
Bullish
Price vs 50-day avg
−4% below
Neutral
RSI (14)
51 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
68% · mid-range
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $32 › 200d $27 — 50d above 200d
Institutional flow
Flat
1 of 163 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.59% of float · ▲ +6.3% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
163 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $31 · 68%
52-wk high $41
vs 200-day avg +13%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $383.5M | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TYRA
this stock
Tyra Biosciences, Inc.
|
$1.82B | +16.5% | — | — | 16.6% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TYRA | -1.0% | +6.7% | +0.9% | -4.1% | +16.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -2.5% | +8.0% | -7.1% | -3.9% | +7.3% |